Episode Details

Back to Episodes
Viral Hepatitis Update: CCO Independent Conference Coverage of EASL 2023

Viral Hepatitis Update: CCO Independent Conference Coverage of EASL 2023

Episode 295 Published 2 years, 8 months ago
Description

In this episode, Stefan Zeuzem, MD, discusses new data on viral hepatitis presented at EASL 2023, including:

  • Hepatitis B virus
    • Durability of response with bepirovirsen
    • HBsAg loss with siRNA VIR-2218 combined with either VIR-3434 (novel monoclonal antibody) or pegIFN-alfa
  • Hepatitis delta virus
    • 96-week follow-up of immediate vs delayed bulevirtide
    • Off-treatment response for lonafarnib + ritonavir ± pegIFN-alfa 
    • Safety and efficacy outcomes with siRNA JNJ-3989 + nucleos(t)ide analogue
  • Hepatitis C virus
    • Collaborative service at opiate substitution treatment clinic to improve linkage to care in Ireland
    • Nurse-led test-and-treat program to increase screening and diagnosis at female prisons in the United Kingdom
    • FIND-C study using machine learning to improve screening-to-diagnosis ratio using clinical factors and social determinants of health

Presenter:

Stefan Zeuzem, MD
Professor of Medicine 
Chief, Department of Medicine 
JW Goethe University Hospital 
Frankfurt, Germany

Link to full program: 

https://bit.ly/3JQQj3J


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Listen Now

Love PodBriefly?

If you like Podbriefly.com, please consider donating to support the ongoing development.

Support Us